WHO Prequalifies More Biosimilars
Celltrion And Mylan See Trastuzumab Biosimilars Added To WHO List
The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.
You may also be interested in...
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
Despite having biosimilars of insulin glargine and etanercept that are expected to launch in the US and Europe respectively midway through this year, a biosimilar bevacizumab candidate filed in both regions, an in-development Botox rival still being considered and several other biosimilars already on the market around the world, Mylan insists that its biosimilars journey is just beginning.
In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.